judge has denied an injunction that prompted the FDA to update their guidance.
The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials
We focus on personalized programs that look at the whole person, not just the BMI
Yes, GLP-1 medication shortages have largely resolved as of 2024, expanding patient access to multiple formulations and dosing options
If you want the cliff notes version, here it is: The GLP-1 agonists reduce blood sugar levels, slow digestion and significantly reduce appetite, making you feel fuller longer and eat less
Teneligliptin, a DPP-4 inhibitor, demonstrated mild antinociceptive effects against heat-induced acute pain, but remarkable analgesic effects against partial sciatic nerve transection (PSNT)-induced neuropathic pain in rats [70]